These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 29262929)

  • 21. Mesenchymal Stromal Cells in Hematopoietic Stem Cell Transplantation.
    Bernardo ME; Locatelli F
    Methods Mol Biol; 2016; 1416():3-20. PubMed ID: 27236663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Unrelated Donor Peripheral Blood Stem Cell Transplantation Combined with Umbilical Cord Mesenchymal Stem Cells in Patients with Hematologic Malignancies].
    Zhang XT; Duan LN; Ding L; Zhu L; Yan HM; Wang ZD; Wang S; Zheng XL; Dong L; Xue M; Liu J; Wang HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1445-50. PubMed ID: 26524054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Research progress on immunologic mechanisms of mesenchymal stem cells for treatment of graft-versus-host disease].
    Wang RP; Chen H; Guo YQ; Wu RN; Zhang B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):550-3. PubMed ID: 21518528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells.
    Le Blanc K; Samuelsson H; Gustafsson B; Remberger M; Sundberg B; Arvidson J; Ljungman P; Lönnies H; Nava S; Ringdén O
    Leukemia; 2007 Aug; 21(8):1733-8. PubMed ID: 17541394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of mesenchymal stromal cells for the prophylaxis of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials.
    Wang L; Zhu CY; Ma DX; Gu ZY; Xu CC; Wang FY; Chen JG; Liu CJ; Guan LX; Gao R; Gao Z; Fang S; Zhuo DJ; Liu SF; Gao CJ
    Ann Hematol; 2018 Oct; 97(10):1941-1950. PubMed ID: 29947972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Umbilical cord-derived mesenchymal stem cells promote myeloid-derived suppressor cell enrichment by secreting CXCL1 to prevent graft-versus-host disease after hematopoietic stem cell transplantation.
    Wang R; Wang X; Yang S; Xiao Y; Jia Y; Zhong J; Gao Q; Zhang X
    Cytotherapy; 2021 Nov; 23(11):996-1006. PubMed ID: 34465514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Umbilical cord mesenchymal stem cells and their association with liver fibrosis].
    Tuo L; Zeng WZ; Xue HL; Wu XL
    Zhonghua Gan Zang Bing Za Zhi; 2017 Jan; 25(1):65-68. PubMed ID: 28297787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Umbilical Cord Blood-Derived Mesenchymal Stromal Cells for Reducing Chronic Graft-Versus-Host Disease After Haploidentical Transplantation: Just Another Labor-Intensive Strategy, or Showing the Way?
    Lazarus HM; Pavletic SZ
    J Clin Oncol; 2016 Aug; 34(24):2812-3. PubMed ID: 27400943
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical evaluation of haploidentical hematopoietic combined with human umbilical cord-derived mesenchymal stem cells in severe aplastic anemia.
    Xu L; Liu Z; Wu Y; Yang X; Cao Y; Li X; Yan B; Li S; Da W; Wu X
    Eur J Med Res; 2018 Mar; 23(1):12. PubMed ID: 29490698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential Use of Mesenchymal Multipotent Cells for Hemopoietic Stem Cell Transplantation: Pro and Contra.
    Kiselevskiy M; Vlasenko R; Reshetnikova V; Chikileva I; Shubina I; Osmanov E; Valiev T; Sidorova N; Batmanova N; Stepanyan N; Kirgizov K; Varfolomeeva S
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):90-94. PubMed ID: 33560076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells with a myeloablative regimen for refractory/relapsed hematologic malignancy.
    Wu Y; Wang Z; Cao Y; Xu L; Li X; Liu P; Yan P; Liu Z; Zhao D; Wang J; Wu X; Gao C; Da W; Han Z
    Ann Hematol; 2013 Dec; 92(12):1675-84. PubMed ID: 23842707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients.
    Sundin M; Ringdén O; Sundberg B; Nava S; Götherström C; Le Blanc K
    Haematologica; 2007 Sep; 92(9):1208-15. PubMed ID: 17666368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter II: emerging transformational cytotherapies.
    Vertès AA
    Regen Med; 2015; 10(3):345-73. PubMed ID: 25933242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II Multicenter, Randomized, Double-Blind Controlled Study of Efficacy and Safety of Umbilical Cord-Derived Mesenchymal Stromal Cells in the Prophylaxis of Chronic Graft-Versus-Host Disease After HLA-Haploidentical Stem-Cell Transplantation.
    Gao L; Zhang Y; Hu B; Liu J; Kong P; Lou S; Su Y; Yang T; Li H; Liu Y; Zhang C; Gao L; Zhu L; Wen Q; Wang P; Chen X; Zhong J; Zhang X
    J Clin Oncol; 2016 Aug; 34(24):2843-50. PubMed ID: 27400949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mesenchymal stem cells versus mesenchymal stem cells combined with cord blood for engraftment failure after autologous hematopoietic stem cell transplantation: a pilot prospective, open-label, randomized trial.
    Xiong YY; Fan Q; Huang F; Zhang Y; Wang Y; Chen XY; Fan ZP; Zhou HS; Xiao Y; Xu XJ; Dai M; Xu N; Sun J; Xiang P; Huang XJ; Liu QF
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):236-42. PubMed ID: 24216182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human bone marrow mesenchymal stromal/stem cells: current clinical applications and potential for hematology.
    Miura Y
    Int J Hematol; 2016 Feb; 103(2):122-8. PubMed ID: 26692196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transplantation of RADA16-BDNF peptide scaffold with human umbilical cord mesenchymal stem cells forced with CXCR4 and activated astrocytes for repair of traumatic brain injury.
    Shi W; Huang CJ; Xu XD; Jin GH; Huang RQ; Huang JF; Chen YN; Ju SQ; Wang Y; Shi YW; Qin JB; Zhang YQ; Liu QQ; Wang XB; Zhang XH; Chen J
    Acta Biomater; 2016 Nov; 45():247-261. PubMed ID: 27592818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.